The approval is supported by data from the phase 3 LITESPARK-011 trial.
Feature|Articles|April 1, 2026
Top 10 urology headlines you missed in Q1 2026
Author(s)Hannah Clarke
Fact checked by: Benjamin P. Saylor, Strategic Content Lead
Take a look through the top 10 stories in urology from the past quarter.
Advertisement
Advertisement
The first quarter of 2026 brought a wave of pivotal developments across urology, from landmark clinical trial results to meaningful FDA actions reshaping treatment standards. Bladder and prostate cancer saw some of the most significant advances, with the KEYNOTE-B15 trial establishing a new perioperative standard of care in muscle-invasive disease and the PRIMARY2 trial offering a smarter diagnostic path that could spare men from unnecessary biopsies.
Related to this article
Pearls & Perspectives: Expanding Sexual Health Conversations Through Digital Media, With Wendy Brant
Amy Pearlman, MD, and Wendy Brant discuss building a digital audience, navigating sexual health content online, and the role of communication in relationships.
Positive safety and efficacy data from 4 clinical studies supported the CE marking.
Sandip Prasad, MD, discusses patient selection for chemoablation in recurrent LG-IR-NMIBC and considerations when counseling patients about a nonsurgical approach.
In a head-to-head RCT, Rezūm produced a 4.6-point greater IPSS improvement than combination pharmacotherapy at 1 year, according to Jean-Nicolas Cornu, MD, PhD, FEBU.
The AACU and the WOCN Society urge CMS to protect access to individualized catheter and ostomy supplies as competitive bidding begins in 2028.
Better detection has changed prostate cancer care. Patients choosing radical treatment still need better protection from the disease returning.
Enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) showed the strongest EFS, OS, and PCR associations among neoadjuvant MIBC strategies in a network meta-analysis, although perioperative design limits attribution.
Advertisement
Advertisement